Acute urinary retention: Medical management and the identification of risk factors for prevention

Nature Clinical Practice Urology

Volumn 4, Issue 8, 2007, Pages 422-431

  Khastgir, Jay ^a   Khan, Azhar ^a   Speakman, Mark ^b  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b MUSGROVE PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PHOSPHOLIPASE C; PLACEBO; PROTEIN C; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

AGE; ALPHA ADRENERGIC RECEPTOR BLOCKING; CATHETER REMOVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSERVATIVE TREATMENT; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; HIGH RISK PATIENT; HUMAN; INCIDENCE; LOWER URINARY TRACT SYMPTOM; MALE; MONOTHERAPY; PHYTOTHERAPY; POSTVOID RESIDUAL URINE VOLUME; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SINGLE DRUG DOSE; URINE RETENTION;

ACUTE DISEASE; ADRENERGIC ANTAGONISTS; DISEASE MANAGEMENT; HUMANS; MALE; PROSTATIC HYPERPLASIA; RISK FACTORS; URINARY CATHETERIZATION; URINARY RETENTION;

EID: 34547841303     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0860     Document Type: Review

References (53)

1. Emberton M and Anson K (1999) Acute urinary retention in men: An age old problem. BMJ 318: 921-925
2. Fitzpatrick JM and Kirby RS (2006) Management of acute urinary retention. BJU Int 97 (Suppl 2): 16-20
3. Girman CJ et al. (1998) Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 51 428-436
4. Welch G et al. (2002) Quality-of-life impact of lower urinary tract symptom severity: Results from the Health Professionals Follow-up Study. Urology 59: 245-250
5. Emberton M et al. (2003) Benign prostatic hyperplasia: A progressive disease of ageing men. Urology 61: 267-273
6. Garraway WM et al. (1991) High prevalence of benign prostatic hypertrophy in the community. Lancet 338: 469-471
7. Jacobsen SJ et al. (1999) Treatment for benign prostatic hyperplasia. among community dwelling men: The Olmsted County study of urinary symptoms and health status. J Urol 162: 1301-1306
8. Berry SJ et al. (1984) The development of human benign prostatic hyperplasia with age. J Urol 132: 474-479
9. Roehrborn CG (2002) Reporting of acute urinary retention in BPH treatment trials: Importance of patient follow-up after discontinuation and case definitions. Urology 59: 811-815
10. Verhamme KM et al. (2002) Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care - the Triumph project. Eur Urol 42: 323-328
11. Jacobsen SJ et al. (1997) Natural history of prostatism: Risk factors for acute urinary retention. J Urol 158: 481-487
12. Pickard R et al. (1998) The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol 81: 712-720
13. Meigs JB et al. (1999) Incidence rates and risk factors for acute urinary retention: The health professionals follow-up study. J Urol 162: 376-382
14. Lee AJ et al. (1998) The natural history of untreated lower urinary symptoms in middle-aged and elderly men over a period of 5 years. Eur Urol 34: 325-332
15. Dobrovits M et al. (2003) A longitudinal prospective study of men with mild symptoms of BOO treated with watchful waiting over 4 years. Eur Urol Suppl 2: 26
16. Girman CJ et al. (1994) Natural history of prostatism: Impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 44: 825-831
17. Trueman P et al. (1999) Prevalence of lower urinary tract symptoms and seff-reported diagnosed 'benign prostatic hyperplasia' and their effect on quality of life in a community-based survey of men in the UK. BJU Int 83: 4110-415
18. Kawakami J and Nickel JC (1999) Acute urinary retention and surgery for benign prostatic hyperplasia. the patient's perspective. Can J Urol 6: 819-822
19. Teillac P (2002) Benign prostatic hyperplasia: Patients' perception of medical treatment and their expectations. Results of a French survey involving patients treated with finasteride [French]. Therapie 57: 473-483
20. Watson V et al. (2004) Eliciting preferences for benign prostatic hyperplasia medical treatment [abstract # 229]. Presented at the XIX EAU Congress, Vienna 2004
21. McConnell JD et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl. J Med 338: 557-563
22. McConnell JD et al. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387-2398
23. Roehrborn CG (2006) Definition of at-risk patients: Baseline variables. BJU Int 97 (Suppl 2): 7-11
24. Kolman C et al. (1999) Distribution of post-void residual urine in randomly selected men. J Urol 161: 122-127
25. Kaplan SA et al. (2006) Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 175: 217-220
26. Roehrborn CG et al. (2004) Impact of baseline PSA and TRUS volume on longitudinal changes in IPSS and maximum flow rate in MTOPS [abstract #911]. J Urol 171: 241
27. Roerhrborn CG (2006) Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute retention: Results of a 2-year placebo-controlled study. BJU Int 97: 734-741
28. Roehrborn CG et al. (2005) The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH. Results from the MTOPS study. J Urol 173 (Suppl): 346
29. Armitage J and Emberton M (2005) Is it time to reconsider the role of prostatic inflammation in the pathogenesis of lower urinary tract symptoms? BJU Int 96: 745-746
30. Emberton M (2005) Definition of at-risk patients: Dynamic variables. BJU Int 97 (Suppi 2): 12-15
31. Emberton M et al. (2005) Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10mg once daily. Urology 86: 316-322
32. Graham RM et al. (1996) Alpha 1-adrenergic receptor subtypes. Molecular structure, function, and signalling. Circ Res 78: 737-749
33. Djavan B and Marberger M (1999) A meta-analysis on the efficacy and tolerability of a1 adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 1-13
34. Jardin A et al. (1991) Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 337: 1457-1461
35. Lukacs B et al. (1998) Three-year prospective study of 3228 clinical BPH patients studied with alfuzosin in general practice. Prostate Cancer Prostatic Dis 5: 276-293
36. McNeill SA et al. (2001) Post-void residual urine in patients with LUTS suggestive of BPH: Pooled analysis of eleven controlled studies with alfuzosin. Urology 57: 459-465
37. Hartung R (2001) Do alpha-blockers prevent the occurrence of acute urinary retention? Eur Urol (Suppl 6): 13-18
38. Kyprianou N et al. (1998) Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 159: 1810-1815
39. Chon JK et al. (1999) Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 161: 2002-2008
40. Tahmatzopoulos A and Kyprianou N (2004) Apoptotic impact of alpha1-blockers; on prostate cancer growth: A myth or an inviting reality? Prostate 59: 91-100
41. Clark RV et al. (2004) Marker suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5a-reductase inhibitor. J Clin Endocrinol Metab 89: 2179-2184
42. Roehborn CG et al. (2000) Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Eur Urol 37 528-536
43. Debruyne F et al. (2004) Efficacy and safety with longterm treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46: 488-494
44. Boyle P et al. (2003) The novel dual 5α-reductase inhibitor dutasteride is effective for the treatment and prevention of complications in men with a PV 30-≤40 cc and 40 cc [abstract #632]. Eur Urol 2 (Suppl): 169
45. de la Rosette JJ et al. (2002) Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms. J Urol 167: 1734-1739
46. Barkin J et al. (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 44: 461-466
47. Chan PS et al. Can terazosin (alpha blocker) relieve acute urinary retention and obviate the need indwelling urinary catheter [abstract #26]. Br J Urol 77 (Suppl): 7
48. Bowden E et al. (2001) Tamsulosin in the treatment of urinary retention: A prospective, placebo-controlled trial [abstract #148). BJU Int 88 (Suppl): 77
49. Lucas MG et al. (2005) Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int 95: 354-357
50. McNeill SA (2004) The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction. Eur Urol 45: 325-332
51. McNeill SA and Hargreave TB (2004) Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. J Urol 171: 2316-2320
52. Desgrandchamps F et al. (2006) Management of acute urinary retention in France: A cross-sectional survey in 2618 men with benign prostatic hyperplasia. BJU Int 97: 727-733
53. McNeill SA et al. (2005) Alfuzosin 10 mg once daily in the management of acute urinary retention: Results of a double-blind placebo-controlled study. Urology 85: 83-90